Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Abemaciclib in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Abemaciclib Capsules (Reference Formulation)
Drug: Abemaciclib Tablet (Test Formulation)

First Posted Date: 2016-02-03

Last Posted Date: 2019-01-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 127

Registration Number: NCT02672423

Locations: 🇺🇸
Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States
🇺🇸
Evansville Clinical Research Unit, Evansville, Indiana, United States

A Study of LY3039478 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3039478 new formulation
Drug: LY3039478 original formulation

First Posted Date: 2016-01-20

Last Posted Date: 2016-07-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT02659865

Locations: 🇺🇸
Covance, Daytona Beach, Florida, United States

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Olaratumab
Drug: Gemcitabine
Drug: Placebo
Drug: Docetaxel

First Posted Date: 2016-01-20

Last Posted Date: 2022-05-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 310

Registration Number: NCT02659020

Locations: 🇺🇸
Georgia Cancer Specialists PC, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 45 locations

A Study of Various Formulations of LY900014 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY900014
Drug: Insulin lispro (Humalog)

First Posted Date: 2015-12-21

Last Posted Date: 2020-05-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 26

Registration Number: NCT02636361

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Fumaric Acid Esters
Drug: Ixekizumab
Drug: Methotrexate

First Posted Date: 2015-12-18

Last Posted Date: 2019-10-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 162

Registration Number: NCT02634801

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany
🇩🇪
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Kiel, Germany

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Conditions: Cancer

First Posted Date: 2015-12-17

Last Posted Date: 2024-11-11

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT02632994

Locations: 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸
UCLA Medical Center, Torrance, California, United States
🇺🇸
Fort Wayne Oncology & Hematology, Fort Wayne, Indiana, United States

A Study of LY3337641 in Rheumatoid Arthritis

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: LY3337641

First Posted Date: 2015-12-11

Last Posted Date: 2019-10-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 286

Registration Number: NCT02628028

Locations: 🇺🇸
Desert Medical Advances, Palm Desert, California, United States
🇺🇸
Stanford University Hospital, Palo Alto, California, United States
🇺🇸
Jeffrey Alper MD Research, Naples, Florida, United States

and more 16 locations

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Biological: LY3002813
Drug: Placebo

First Posted Date: 2015-12-08

Last Posted Date: 2024-10-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 61

Registration Number: NCT02624778

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
🇺🇸
Brain Matters Research, Delray Beach, Florida, United States
🇺🇸
SNBL Clinical Pharmacology Center Inc, Baltimore, Maryland, United States

and more 4 locations